A Real World Study Evaluating the Cardiac Effects of the Migalastat in Patients with Fabry Disease having Amenable Mutations of α-Galactosidase A

Trial Profile

A Real World Study Evaluating the Cardiac Effects of the Migalastat in Patients with Fabry Disease having Amenable Mutations of α-Galactosidase A

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 30 Sep 2017 New trial record
    • 30 Aug 2017 Initial results of follow up visit 1 (n=6) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top